Keyword Analysis & Research: revolution medicines
Keyword Research: People who searched revolution medicines also searched
Search Results related to revolution medicines on Search Engine
-
Pipeline - Revolution Medicines
https://www.revmed.com/pipeline/
WEBRevolution Medicines is building a deep pipeline in support of its focus on the development and delivery of novel targeted therapies to patients with RAS-addicted cancers.
DA: 31 PA: 20 MOZ Rank: 62
-
Investor Relations | Revolution Medicines
https://ir.revmed.com/
WEBRevolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies.
DA: 90 PA: 3 MOZ Rank: 54
-
Revolution Medicines Completes Acquisition of EQRx - Yahoo …
https://finance.yahoo.com/news/revolution-medicines-completes-acquisition-eqrx-141000106.html
WEBREDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers,...
DA: 62 PA: 60 MOZ Rank: 29
-
Revolution Medicines Doses First Patient in Phase 1/1b Clinical …
https://finance.yahoo.com/news/revolution-medicines-doses-first-patient-110000377.html
WEBSep 19, 2023 · Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS (ON) Inhibitors designed to...
DA: 41 PA: 58 MOZ Rank: 29
-
Revolution Medicines Completes Acquisition of EQRx
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-completes-acquisition-eqrx
WEBREDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.
DA: 46 PA: 85 MOZ Rank: 55
-
Revolution Medicines Doses First Patient in Phase 1/1b Clinical …
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-phase-11b-clinical-0
WEBREDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRAS G12D …
DA: 37 PA: 9 MOZ Rank: 87
-
Revolution Medicines Announces Publication on the Discovery of …
https://finance.yahoo.com/news/revolution-medicines-announces-publication-discovery-193400860.html
WEBREDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with...
DA: 23 PA: 93 MOZ Rank: 16
-
Revolution Medicines, Inc. to Acquire EQRx, Inc. in
https://www.globenewswire.com/news-release/2023/08/01/2715636/0/en/Revolution-Medicines-Inc-to-Acquire-EQRx-Inc-in-All-Stock-Transaction-to-Gain-More-Than-1-Billion-in-Additional-Capital.html
WEBAug 1, 2023 · REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (“Revolution Medicines” or the “Company”) (Nasdaq: RVMD), a clinical-stage oncology...
DA: 24 PA: 42 MOZ Rank: 24
-
Revolution Medicines Presents Promising Clinical Activity
https://www.globenewswire.com/news-release/2023/10/22/2764319/0/en/Revolution-Medicines-Presents-Promising-Clinical-Activity-and-Safety-Data-from-Phase-1-1b-Trial-of-RMC-6236.html
WEBREDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers,...
DA: 21 PA: 77 MOZ Rank: 44
